Association between the Replication Capacity and Mother‐to‐Child Transmission of HIV‐1, in Antiretroviral Drug–Naive Malawian Women
1Department of Pathology, Johns Hopkins University School of Medicine, and 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 3Monogram Biosciences, South San Francisco, California; 4Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, Piscataway, New Jersey; 5Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill
Replication capacity and transmission of human immunodeficiency virus (HIV)–1 in antiretroviral drug–naive Malawian women who had subtype C infection were investigated. Infant children of these women received either 1 dose of nevirapine or 1 dose of nevirapine plus 1 week of daily doses of zidovudine. PhenoSense HIV was used to determine replication capacity in 49 women whose infants were infected with HIV‐1 and in 47 women whose infants were uninfected by 6–8 weeks of age. Mean replication capacity was higher in transmitters than in nontransmitters (
). In a multivariate model, higher replication capacity was associated with transmission (odds ratio, 1.45 for each 10% increase in replication capacity [95% confidence interval, 1.11–1.90]; P
=
.0063), after adjustment for maternal HIV‐1 load and other factors.
Received 9 November 2005; accepted 11 January 2006; electronically published 20 April 2006.
Cited by
Online publication date: 1-Jun-2009.
CrossRef
Online publication date: 1-Apr-2008.
CrossRef
Online publication date: 1-Apr-2007.
CrossRef
-
Conflicts of interest: Y.L., C.J.P., and N.P. are employed by and are stockholders of Monogram Biosciences, which performs the PhenoSense HIV assay.
Financial support: HIV Prevention Trials Network, sponsored by the National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, National Institutes of Health (NIH), Department of Health and Human Services (grants U01‐AI‐46745 and U01‐AI‐48054); NIH (grant R01‐HD042965‐01); Fogarty International Center, NIH (AIDS FIRCA award 5R03TW01199 and supplement); National Institute of Allergy and Infectious Diseases (Small Business Innovation Research grant R44 AI050321‐03A1, for development of the Monogram PhenoSense HIV Replication Capacity assay); The Doris Duke Charitable Foundation, New York; National Science Foundation Energy Information Administration (grant 02‐05116).





